DELIVERY OF THERAPEUTICALLY/DERMATOLOGICALLY ACTIVE SPECIES INTO THE SKIN VIA ELECTROPORATION

• US 20100210994A1
• Filed: 08/14/2009
• Published: 08/19/2010
• Est. Priority Date: 02/20/2007
• Status: Abandoned Application

• Current Assignee: Galderma Research And Development Snc (Nestle SA)
• Original Assignee: Galderma Research And Development Snc (Nestle SA)
• Inventors: Zarif, Leila
• Application Number:
  US12/541,376
• Publication Number:
  US 20100210994A1
• Time in Patent Office: Days
• US Class Current: 604/20
• CPC Class Codes: A61N 1/0416 Anode and cathode
• CPC Class Codes: A61N 1/0476 Array electrodes (including any electrode arrangement with more than one electrode for at least one of the polarities)
• CPC Class Codes: A61N 1/327 for enhancing the absorption properties of tissue, e.g. by electroporation

Abstract

A regime or regimen for treating a skin disease, disorder or condition afflicting a patient in need thereof includes forming at least one micropore to a predetermined depth through a surface of the afflicted skin of such patient; positioning at least a first electrode on the surface of the afflicted skin electrically coupled to the at least one micropore and a second electrode on the surface of the afflicted skin spaced apart from the first electrode; applying an electrical voltage from the first and second electrodes to produce a desired electroporation in the skin, and further including the step of delivering a biologically active species to the afflicted skin at the at least two micropores formed therein, wherein the biologically active species is therapeutically/dermatologically active against the skin disease, disorder or condition.

Claims

1. A regime or regimen for treating a skin disease, disorder or condition afflicting a patient in need thereof,

which method comprises

a) forming at least one micropore to a predetermined depth through a surface of the afflicted skin of said patient;

b) positioning at least a first electrode on the surface of the skin electrically coupled to the at least one micropore and a second electrode on the surface of the skin spaced apart from the first electrode;

c) applying an electrical voltage from the first and second electrodes to produce a desired electroporation in the skin,

and further comprising the step d) of delivering a biologically active species to the skin at the at least two micropores formed therein, wherein the said biologically active species is therapeutically/dermatologically active against said skin disease, disorder or condition.

2. The regime or regimen as defined by claim 1, wherein step c) comprises applying an electrical voltage of a sufficient magnitude from the first and second electrodes suitable to produce a potential drop exceeding a nominal threshold to achieve electroporation across the epithelial cell layer but not sufficient to electroporate membranes present in other skin structures, thereby achieving a selective electroporation of targeted membranes.

3. The regime or regimen as defined by claim 1, wherein step a) comprises forming first and second micropores spaced apart from each other, and wherein the first electrode is positioned to be electrically coupled to the first micropore, and the second electrode is positioned to be electrically coupled to the second micropore.

4. The regime or regimen as defined by claim 1, wherein step c) comprises applying a voltage pulse of a first polarity with respect to the first and second electrodes, followed by a voltage pulse of an opposite polarity with respect to the first and second electrodes.

5. The regime or regimen as defined by claim 1, wherein step a) comprises forming a plurality of micropores spaced apart from each other in the skin, and step b) comprises placing a plurality of electrodes each being electrically coupled to a different one of the micropores, and wherein step c) comprises applying electrical voltage pulses from different sets of the plurality of electrodes so as to electroporate the skin in multiple directions.

6. The regime or regimen as defined by claim 5, wherein step c) comprises applying a voltage pulse of a first polarity from a first set of electrodes followed by a voltage pulse of an opposite polarity from the first set of electrodes.

7. The regime or regimen as defined by claim 1, wherein step a) comprises applying a photosensitizing material to the surface of the afflicted skin and irradiating the photosensitizing material with optical energy, whereby the photosensitizing material is responsive to the optical energy so as to heat up and conductively transfer heat to the surface of the skin to form the at least one micropore.

8. The regime or regimen as defined by claim 1, further comprising the step e) of deforming the surface of the afflicted skin from the first and second electrodes such that the surface of the afflicted skin sufficiently bulges from the first and second electrodes to place skin structures desired to be electroporated in a principal current path from the first and second electrodes.

9. The regime or regimen as defined by claim 1, wherein step a) comprises applying a photosensitizing material to the surface of the afflicted skin and irradiating the photosensitizing material with optical energy, whereby the photosensitizing material is responsive to the optical energy such as to heat up and conductively transfer heat to the surface of the afflicted skin to form the at least one micropore, whereby the step of positioning the first and second electrodes comprises positioning conductive traces on a skin-contacting side of the photosensitizing material registered with the micropores.

10. The regime or regimen as defined by claim 1, wherein said disease, disorder or condition is selected from the group consisting of:

dermatological conditions associated with a keratinization disorder relating to differentiation and to proliferation, acne, common acne, comedo-type acne, polymorphic acne, rosacea, nodulocystic acne, acne conglobata, senile acne, and secondary acne, solar, drug-related or occupational acne;

ichthyoses, ichthyosiform conditions, Darrier'"'"'s disease, palmoplantar keratoderma, leukoplakia and leukoplakiform conditions, cutaneous lichen;

dermatological conditions with an inflammatory immunoallergic component, with or without a cell proliferation disorder, psoriasis, cutaneous, mucosal or ungual psoriasis, psoriatic rheumatism, cutaneous atopy, atopic dermatitis, eczema, respiratory atopy or gingival hypertrophy,

benign or malignant dermal or epidermal proliferations, of viral or non-viral origin, common warts, flat warts, epidermodysplasia verruciformis, oral or florid papillomatoses, T lymphoma,

proliferations which may be induced by ultraviolet light, basal cell epithelioma and spinocellular epithelioma,

precancerous and cancerous skin lesions, keratoacanthomas and melanoma,

immune dermatoses, lupus erythematous,

bullous immune diseases,

dermatological symptoms of collagen diseases, scleroderma,

dermatological conditions with an immunological component,

skin disorders due to exposure to UV radiation, or light-induced or chronological aging of the skin, or actinic keratoses and pigmentations, lentigines, or any pathologies associated with chronological or actinic aging, xerosis,

sebaceous function disorders, hyperseborrhoea acne or simple seborrhoea or seborrhoeic dermatitis,

cicatrization disorders or stretch marks,

pigmentation disorders, hyperpigmentation, melasma, chloasma, plane pigmented seborrheic warts, nevi, freckles, ephelides, actinic keratosis, hyperpigmentations with genetic determinism, hyperpigmentations of metabolic or medicamentous origin, melanoma, post-inflammatory hyperpigmentations, those caused by abrasion, burn, scar, dermatitis, contact allergy, hyperpigmentations due to a skin trouble, psoriasis, rosacea, atopic dermatitis all other hyperpigmented lesions, hypopigmentation or vitiligo, and

alopecia of various origins, and alopecia caused by chemotherapy or radiation.

11. The regime or regimen as defined by claim 10, wherein said disease, disorder or condition is selected from the group consisting of acne, atopic dermatitis, psoriasis, rosacea, hyperpigmentation, melasma and melanoma.

12. The regime or regimen as defined by claim 11, wherein said disease, disorder or condition comprises acne.

13. The regime or regimen as defined by claim 11, wherein said disease, disorder or condition comprises psoriasis.

14. The regime or regimen as defined by claim 11, wherein said disease, disorder or condition comprises melasma.

15. The regime or regimen as defined by claim 11, wherein said disease, disorder or condition comprises rosacea.

16. The regime or regimen as defined by claim 1, wherein said disease, disorder or condition comprises melanoma.

17. The regime or regimen as defined by claim 1, wherein said biologically active species is selected from the group consisting of a retinoid, vitamin D and derivative thereof, a corticosteroid, an estrogen, an antibacterial agent, an anti-parasitic agent, an anti-fungal agent, a polyene compound, compounds of the allylamine family, compounds of the pyridinone family, steroidal anti-inflammatories, non-steroidal anti-inflammatories, anaesthetics;

antiseptics;

anti-pruriginous agents, anti-viral agents;

keratolytic agents;

free-radical scavengers, anti-seborrhoeic agents;

anti-dandruff agents;

anti-acne agents, anti-metabolites;

agents for combating hair loss; and

biologicals.

18. The regime or regimen as defined by claim 1, wherein said biologically active species is selected form the group consisting of estradiol, calcitriol, calcipotriol, fluocinolone acetonide, kojic acid, hydroquinone, clindamycin phosphate, erythromycin, antibiotics of the tetracycline class, metronidazole, ivermectin, crotamiton, pyrethrinoids, econazole, ketoconazole, miconazole, or salts and derivatives thereof, amphotericin B, terbinafine, cyclopirox, amorolfine, hydrocortisone, dioxyanthranol, anthranoids, betamethasone valerate, clobetasol 17-propionate, ibuprofen and salts or derivatives thereof, diclofenac and salts and derivatives thereof, acetylsalicylic acid, acetaminophen, glycyrrhetinic acid, lidocaine, lidocaine hydrochloride, tetracaine, pilocalne and derivatives thereof;

thenaldine, trimeprazine or cyproheptadine, acyclovir, glycolic acid, lactic acid, malic acid, salicylic acid, citric acid and fruit acids, 5-n-octanoyl-salicylic acid, alpha-tocopherol or esters thereof, superoxide dismutases, ascorbic acid and esters thereof, progesterone, octopirox, zinc pyrithione;

retinoic acid, benzoyl peroxide, adapalene, acitretin, etretinate, isotretinoin, tretinoin, tazarotene, compounds described in FR-2-570,377, EP-1 99,636, EP-325,540 and EP-402,072, rucinol, mequinol, retinol, minoxidil, hormones, peptides, antibodies and nucleic acids.

19. A regime or regimen for treating a skin disease, disorder or condition afflicting a patient in need thereof, which method comprises:

a) forming at least one micropore to a predetermined depth through a surface of the skin by placing an electrically heated probe at the surface of the afflicted skin and supplying electrical current to the electrically heated probe so as to ablate the surface of the afflicted skin to form the at least one micropore;

b) positioning at least a first electrode electrically coupled to the at least one micropore and a second electrode spaced apart from the first electrode;

c) applying an electrical voltage from the first and second electrodes to produce a desired electroporation in the skin,

and further comprising the step d) of delivering a biologically active species to the skin at the at least two micropores formed therein, wherein said biologically active species is therapeutically/dermatologically active against said disease, disorder or condition.

20. The regime or regimen as defined by claim 19, wherein the electrically heated probe also serves as the first electrode such that the electrical voltage is applied from the electrically heated probe and the second electrode.

21. A regime or regimen for treating a skin disease, disorder or condition afflicting a patient in need thereof, which method comprises:

a) forming at least one micropore to a predetermined depth through a surface of the afflicted skin by placing first and second electrically heated probes at the surface of the skin spaced apart from each other and supplying electrical current to each of the first and second electrically heated probes such as to ablate the surface of the afflicted skin in order to form two micropores spaced apart from each other;

b) positioning at least a first electrode electrically coupled to the at least one micropore and a second electrode spaced apart from the first electrode;

c) applying an electrical voltage from the first and second electrodes to produce a desired electroporation in the afflicted skin.

and further comprising the step d) of delivering a biologically active species to the skin at the at least two micropores formed therein, wherein the biologically active species is therapeutically/dermatologically active against said disease, disorder or condition.